Dan Michael Falk - 18 Mar 2026 Form 3 Insider Report for Evogene Ltd. (EVGN)

Role
Director
Signature
/s/ Nitsan Deutsch, attorney-in-fact
Issuer symbol
EVGN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 08:03:42 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Falk Dan Michael Director 10 HAALIYA HASHNIYA ST., HERZELIYA, ISRAEL /s/ Nitsan Deutsch, attorney-in-fact 18 Mar 2026 0001966097

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 1,800 $10.51 Direct
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 1,800 $6.03 Direct
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 1,800 $7.16 Direct
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 2,500 $1.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.